Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Addressing Relapsed Disease Following Hematopoietic Stem Cell Transplantation

John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): SCI1.

https://doi.org/10.1182/blood-2020-133093

Published: 2020

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-133891

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

Armin Ghobadi, MD, Kahee A Mohammed, MDMPH, Rawan Faramand, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Nicholas J. Short, MD, Feng Gao, MD PhD MPH, Geoffrey L Uy, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Richard E. Champlin, MD, Farhad Ravandi, MBBS, Partow Kebriaei, MD

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-141143

Published: 2020

Journal Articles

Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT)

Hind Alotaibi, MBBS, Mahmoud Aljurf, Regis Peffault De Latour, MD PhD, Shahid Iqbal, Andrea Bacigalupo, Judith Marsh, Hubert Schrezenmeier, Eliane Gluckman, Mansour Alfayez, Britta Hoechsmann, Constantijn Halkes, Josu de la Fuente, Nawal AlShehry, Simone Cesaro, Jakob Passweg, Carlo Dufour, Antonio Risitano, John F. DiPersio, MD PhD, Ibraheem Motabi

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140846

Published: 2020

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Geoffrey L Uy, MD, Michael P. Rettig, PhD, Stephanie Christ, MS, Ibrahim Aldoss, MD, Michael T. Byrne, DO, Harry P. Erba, MD PhD, Martha L. Arellano, MD, Matthew C Foster, MD, John E. Godwin, MD, Farhad Ravandi, MBBS, Peter H. Sayre, MDPhD, Anjali S Advani, MD, Matthew J. Wieduwilt, MD PhD, Ashkan Emadi, MD, PhD, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Martin Wermke, Norbert Vey, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Antonio Curti, MDPhD, Geert Huls, MD PhD, Max S. Topp, MD, Mojca Jongen-Lavrencic, MD PhD, John Muth, MS, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MDPhDMS, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-134612

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136919

Published: 2020

Journal Articles

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Max S. Topp, MD, Antonio Curti, MDPhD, Farhad Ravandi, MBBS, Michael P. Rettig, PhD, John Muth, MS, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Teia Curtis, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-134576

Published: 2020

Journal Articles

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Andrew J Menssen, BA, Ajay Khanna, Christopher A Miller, PhD, Gue Su Chang, PhD, Jin J Shao, Sridhar Nonavinkere Srivatsan, MS, Joshua Robinson, Michelle O'Laughlin, Catrina Fronick, BS, Robert Fulton, MS, Kimberly J Brendel, Sharon E Heath, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD, Daniel C. Link, MD, Meagan A. Jacoby, Eric Duncavage, MD, Timothy J Ley, MD, Matthew J. Walter, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140394

Published: 2020

Journal Articles

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142205

Published: 2020

Journal Articles

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

Armin Ghobadi, MD, Michael P. Rettig, PhD, Amanda F Cashen, MD, Leah Gehrs, Stephanie Christ, MS, Neha Mehta-Shah, MD, Peter Westervelt, MD PhD, Brad S. Kahl, MD, Nancy L. Bartlett, MD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142464

Published: 2020

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140541

Published: 2020

Journal Articles

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Kevin A. Goncalves, PhD, Sharon L. Hyzy, MS, Katelyn J. Hammond, BS, Patrick C. Falahee, PhD, Haley Howell, BS, BA, Jan Pinkas, PhD, Veit Schmelmer, PhD, Jonathan G. Hoggatt, PhD, David T. Scadden, MD, Steven M Devine, MD, John F. DiPersio, MD PhD, Will J. Savage, MDPhD, John C. Davis, Jr., MD MPH, MS

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142804

Published: 2020

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Daniel Cancilla, BS, Haresh Thakellapalli, Marvin J Meyers, PhD, Michael P. Rettig, PhD, Ezhilarasi Chendamarai, PhD, Stephanie Christ, MS, Darja Karpova, PhD, Peter G Ruminski, BS, Julie K. Ritchey, Dwight M. Morrow, PhD, Michael Prinsen, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 1916.

https://doi.org/10.1182/blood-2019-124373

Published: 2019

Journal Articles

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Parmeshwar Amatya, PhD, Matthew L. Cooper, PhD, Alun J Carter, PhD BSc, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2068.

https://doi.org/10.1182/blood-2019-126165

Published: 2019

Journal Articles

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2019) 134 (Supplement_1): 1961.

https://doi.org/10.1182/blood-2019-127523

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

NARROW

Addressing Relapsed Disease Following Hematopoietic Stem Cell Transplantation

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only